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Purpose or Objective: To the present, the role of induction 
chemotherapy has remained a subject of controversy. In this 
study, we directly compared the survival of patients 
receiving induction chemotherapy using docetaxel or 
platinum given before concomitant chemoradiotherapy 
(CCRT) with upfront chemoradiotherapy alone. 
 
Material and Methods: The National Health Insurance claims 
database and cancer registry databases from The 
Collaboration Center of Health Information Application in 
Taiwan were linked for the analysis. Head and neck cancer 
patients from January 1, 2002 to December 31, 2011 were 
included in the study. The follow-up duration was from the 
index day to December 31, 2013. The inclusion criteria were 
having a head and neck cancer (identified according to the 
International Classification of Diseases, Ninth Revision, 
Clinical Modification [ICD-9-CM] codes 140.0~148.9), being 
aged > 20 years, being at American Joint Committee on 
Cancer (AJCC) clinical cancer stage III or IV, and having 
undergone induction chemotherapy or platinum-based CCRT. 
Exclusion criteria were having been diagnosed with cancer 
before the head and neck cancer was confirmed, having 
distant metastasis, being at AJCC clinical cancer stages I or 
II, having platinum and docetaxel combined use before 
radiotherapy (RT), being younger than 20 years, one's gender 
being unknown, and having docetaxel use during or after RT, 
induction chemotherapy beyond 8 weeks before RT, only one 
course of induction chemotherapy before RT, cetuximab use, 
adjuvant chemotherapy within 90 days after completion of 
RT, <7000 cGy dose of RT, curative head and neck cancer 
surgery before RT, nasopharyngeal cancer, carcinoma in situ, 
a sarcoma, and head and neck cancer recurrence. The total 
number of enrolled head and neck cancer patients was 
30,990 persons. 
 
Results: In total, 10,721 stage III or IV head and neck cancer 
patients without distant metastasis were included in the 
study, and the median follow-up duration was 4.18 
(interquartile range, 3.25) years. There were 7968 patients in 
the CCRT group (arm 1); 503 patients in the induction 
chemotherapy with docetaxel group of arm 2, and 2232 
patients in the induction chemotherapy with platinum group 
of arm 3. We used the CCRT arm as the control arm to 
investigate the risk of death after induction chemotherapy. 
After adjusting for age, gender, clinical stage, and 
comorbidities, the adjusted hazard ratios (HRs) of overall 
deaths were 1.37 (95% confidence interval [CI], 1.22~1.53) in 
arm 2 and 1.44 (95% CI, 1.36~1.52) in arm 3. In a disease-
specific survival rate analysis, the adjusted HRs of head and 
neck cancers deaths were 1.29 (95% CI, 1.14~1.46) in arm 2 
and 1.47 (95% CI, 1.38~1.56) in arm 3. 
 
Conclusion: Our cohort study showed that induction 
chemotherapy with docetaxel or platinum did not improve 
survival and also resulted in more all-causes death and head 
and neck cancer death risks compared to CCRT. 
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Purpose or Objective: Evidence suggests that gross tumor 
volume (GTV) is a prognostic factor (PF) for laryngeal cancer 
beyond TNM staging. Lower neck lymph nodes (LWNK-LNs) 
have been linked to increased risk of distant metastasis (DM) 
although are generally evident when upper neck disease also 
exists. We hypothesized that primary GTV (GTV-T) and total 
lymph node (LN) GTV (GTV-N) may differentially impact 
overall survival (OS) and DM, and that LWNK-LN may lack 
independent effect. 
 
Material and Methods: All newly diagnosed laryngeal cancers 
treated with definitive intensity modulated radiotherapy 
(IMRT) +/- chemotherapy in 2005-2012 were included. GTV-T 
and GTV-N were delineated for IMRT treatment (confirmed 
with staging CT/MRI) and peer-reviewed at quality assurance 
meetings. Levels IV or Vb LNs were considered LWNK-LNs. 
GTV-N was the summed LN volume receiving full-prescribed 
dose (lower doses were occasionally used to spare brachial 
plexus). OS and distant control (DC) were compared between 
larger/smaller GTV-T, GTV-N (both dichotomized at median 
value), and presence/absence of LWNK-LN. Multivariate 
analysis (MVA) identified PFs for OS and DM. 
 
Results: A total of 635 cases [456 (72%) glottic, 164 (26%) 
supra- and 15 (2%) sub-glottic cancers] were included. TNM 
stages were I: 215 (34%), II: 161 (25%), III: 129 (20%), and IV 
130 (20%). Gross LNs were present in 131 (21%) patients. 
LWNK-LNs were present in 55/131 (42%) cases, all of which 
also had overt LNs in the upper neck (levels 2 +/- 3). Median 
GTV-T was 4 cc (range: 0.1-234.0) and GTV-N was 8 cc 
(range: 0.9-178.0). Systemic agents were used in 81 (13%) 
patients. Larger GTV-T (>=4 cc vs <4 cc) or GTV-N (>8 cc vs 
<=8 cc), or presence of LWNK-LN had inferior 3-year OS (GTV-
T: 65% vs 89%; GTV-N: 37% vs 75%; LWNK-LN: 41% vs 65%, all 
p<0.001) and DC (GTV-T: 87% vs 97%; GTV-N: 71% vs 87%; 
LWNK-LN: 72% vs 84%, all p<0.001). MVA (adjusted for 
treatment) confirmed that TNM stage was the strongest PF 
for OS [III/IV vs I/II: HR 2.52 (1.78-3.56), p<0.001] and DM 
[HR 6.24 (2.67-14.57), p<0.001]. GTV-T (per 10 cc increment) 
was also a PF for OS [HR 1.15 (1.07-1.23), p<0.001] and DM 
[HR 1.18 (1.03-1.36), p=0.015]. GTV-N was a PF for OS [HR 
1.13 (1.07-1.20), p<0.001] but not for DM (p=0.22). LWNK-LN 
was not a PF for OS (p=0.18) nor for DM (p=0.67) although it 
became significant for OS [HR 1.97 (1.32-2.93), p<0.001] 
when GTV-T and GTV-N were excluded from the MVA model. 
 
Conclusion: The TNM classification remains the strongest PF 
for OS and DM. GTV-T is also a PF for OS and DM in addition 
to TNM. GTV-N is a PF for OS but not for DM. Presence of 
LWNK-LN is always associated with upper neck LN 
involvement (likely a surrogate for lymph node burden), and 
seems to lack independent impact on DM and OS if controlling 
for GTV-T and GTV-N. 
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Purpose or Objective: Neck fibrosis is an important 
complication following radio(chemo-)therapy (R(C)T) for head 
and neck cancer (HNC). The purpose of this study was to find 
a parameter that could predict late neck fibrosis and to make 
a multivariate model to predict neck fibrosis grade ≥ 2 
(fibrosis RTOG2-4) at 6 months following R(C)T for HNC. 
 
Material and Methods: We prospectively included 193 
patients in 5 different RT centers for a randomized controlled 
trial. On this patient-population we tested age, sex, T/N 
stage, tumor site, concomitant chemotherapy, upfront neck 
dissection, neo-adjuvant chemotherapy, accelerated RT, 
smoking (never-former-current), alcohol abuse (never-
former-current), the dose prescribed to the elective neck and 
erythema at the end of treatment for their potential to 
predict neck fibrosis RTOG2-4 6 months after the end of 
treatment. Fisher's exact test and Mann-Whitney U test were 
used for testing the association between fibrosis grade 0-1 
versus fibrosis grade 2-4 with categorical or continuous 
variables, respectively. A stepwise selection procedure was 
made to determine the best combination of predictor 
variables for fibrosis RTOG2-4 at 6 months. The area under 
the ROC curve (AUC) was determined for the selected model. 
Additionally a bootstrap-corrected AUC value was calculated. 
This AUC value corrects for over optimism resulting from the 
fact that model construction and model validation were 
performed on the same data set. All tests are two-sided; a 5% 
significance level is considered for all tests. 
 
Results: Upfront neck dissection (p<0.01), erythema at the 
end of R(C)T ≥ grade 3 (p<0.01), increasing N stage (p<0.01) 
and cancer of unknown primary (p=0.02) are significantly 
associated with the incidence of fibrosis RTOG2-4 at 6 
months in our patient population in univariate analysis. 
Upfront neck dissection and erythema grade ≥3 at the end of 
R(C)T were identified for our model using a stepwise 
selection procedure. Additionally, increasing N stage was 
selected as an independent predictor variable (Table 1).  
 
The AUC for this model containing upfront neck dissection, 
erythema at the end of treatment and smoking status was 
0.92; the bootstrap-corrected AUC was 0.90. The risk for 
fibrosis RTOG2-4 at 6 months can be calculated using the 
following formula: 
 
 
 
Conclusion: A model for the prediction of fibrosisRTOG2-4 
following R(C)T for head and neck cancer is presented withan 
AUC of 0.92. Erythema at the end of R(C)T is associated with 
RTOG2-4 fibrosisat 6 months. 
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Purpose or Objective: To determine if the remaining 
submandibular gland volume after surgery is a prognostic 
factor for late xerostomia after postoperative radiotherapy 
(PORT) for head and neck cancer (HNC). 
 
Material and Methods: This prospective cohort study 
consisted of 198 HNC patients who received PORT. The 
primary endpoint was CTCAE v4.0 grade 2 or higher physician 
rated xerostomia at 6 months after completing PORT 
(XERM6). From a set of factors deemed relevant in relation to 
the endpoint (patient characteristics, treatment details, 
surgical data, dosimetric data of major and minor salivary 
glands and oral cavity) a subset of candidate factors was 
selected, using expert knowledge and model exploration. 
Manual stepwise logistic regression was performed with the 
aim to build a strong and valid parsimonious prediction model 
for XERM6. 
 
Results: XERM6 was observed in 54 patients (27.3%). The 
number of remaining submandibular glands was 2 (n=42, 
average remaining volume: 18.7 cm³); 1 (n=105, average 
remaining volume: 9.0 cm³); or 0 (n=51). Patients underwent 
surgery in the oral region (n=154) or in the hypopharyngeal / 
laryngeal region (n=44). The multivariable analysis revealed 
the following independent prognostic factors for the final 
model: baseline xerostomia ≥ grade 1 (OR: 2.978, 95%CI: 
1.363-6.504); ipsilateral parotid mean dose (OR: 1.035 per 
Gy, 95%CI: 1.007-1.065); contralateral parotid mean dose 
(OR: 1.019 per Gy, 95%CI: 0.984-1.056); and the remaining 
total submandibular gland volume (OR: 0.908 per cm³, 95%CI: 
0.855-0.964). This model calibrated well with the observed 
data (Hosmer & Lemeshow test: p = 0.798) and had a good 
performance (Nagelkerke adjusted R²: 0.223, and ROC-AUC: 
0.758). Effect sizes and performance measures were not 
significantly different after internal validation using cross-
validation. 
 
Conclusion: With a similar dose in the parotid glands, the 
risk of late xerostomia increased significantly with less 
remaining submandibular gland volume after surgery. This 
effect is not accounted for in excisting models for late 
xerostomia. The proposed model is the first model 
specifically valuable for predicting late xerostomia in HNC 
patients receiving PORT. 
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Purpose or Objective: To investigate the body image in head 
and neck cancer patients treated with radiotherapy. 
 
Material and Methods: A cross-sectional survey of 150 
patients with head and neck cancer, 60 patients were 
nasopharyngeal cancer (NPC) treated by definite 
radiotherapy without surgery, and 90 patients were oral 
cavity cancer (OCC) treated by radical surgery plus adjuvant 
radiotherapy. All participants completed a 10-item Body 
Image Scale (BIS) to assess the body image dissatisfaction. In 
all patients, the clinical and socio-demographic variables 
were cancer type, age, gender, partnership, education, and 
employment. In OCC patients, the socio-demographic 
variables were the same, and clinical variables were facial 
skin sacrificed, mouth angle sacrificed, glossectomy, 
maxillectomy, and mandibulectomy. ANOVA, t-test, and 
multiple regression were used to evaluate the relationships 
between these variables and BIS. 
 
Results: In all patients, the cancer type (NPC vs. OCC) was 
the strongest independent predictor of BIS. The non-
surgically treated NPC patients had significantly better body 
